ArticleInternational journal of environmental research and public health2013
Biomedical progress rates as new parameters for models of economic growth in developed countries.
Article in International journal of environmental research and public health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploring quality of death in Chinese hospice and palliative care units: a qualitative perspective from practitioners in healthcare settings.BMC palliative care · 2025Article
- Calorie restriction mimetics against aging and inflammation.Biogerontology · 2025Review
- Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers.Scientific reports · 2019Article
- Population Specific Biomarkers of Human Aging: A Big Data Study Using South Korean, Canadian, and Eastern European Patient Populations.The journals of gerontology. Series A, Biological sciences and medical sciences · 2018Article
- Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.Oncotarget · 2018Article
- Geroprotectors: A Unified Concept and Screening Approaches.Aging and disease · 2017Review
- Article
- Editorial: Should We Treat Aging as a Disease? Academic, Pharmaceutical, Healthcare Policy, and Pension Fund Perspectives.Frontiers in genetics · 2016Article
- Article
- Classifying aging as a disease in the context of ICD-11.Frontiers in genetics · 2015Article
- Longevity expectations in the pension fund, insurance, and employee benefits industries.Psychology research and behavior management · 2015Article
- Article
- Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs.Frontiers in genetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the doubling of life expectancy in developed countries during the 20th century can be attributed mostly to decreases in child mortality, the trillions of dollars spent on biomedical research by governments, foundations and corporations over the past sixty years are also yielding longevity dividends in both working and retired population. Biomedical progress will likely increase the healthy productive lifespan and the number of years of government support in the old age. In this paper we introduce several new parameters that can be applied to established models of economic growth: the biomedical progress rate, the rate of clinical adoption and the rate of change in retirement age. The biomedical progress rate is comprised of the rejuvenation rate (extending the productive lifespan) and the non-rejuvenating rate (extending the lifespan beyond the age at which the net contribution to the economy becomes negative). While staying within the neoclassical economics framework and extending the overlapping generations (OLG) growth model and assumptions from the life cycle theory of saving behavior, we provide an example of the relations between these new parameters in the context of demographics, labor, households and the firm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.